Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV-CORE 004 HIV vaccine safety and immunogenicity study in healthy Kenyan adults
PACTR201403000794397Completed
- Sponsor
- University of Oxford
- Start
- Mar 2014
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of Ad35-GRIN, MVA.HIVconsv and pSG2.HIVconsv DNA in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of Oxford. Primary endpoints: Vaccine safety and Vaccine immunogenicity. Started Mar 2014; status: completed.
02
Drugs
Ad35-GRINMVA.HIVconsvpSG2.HIVconsv DNA
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201403000794397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201403000794397.